A great day ahead in Waltham, MA at the Madrigal Pharmaceuticals 2024 Patient Advocate Summit. Opening this interactive day with CEO, Bill Sibold’s welcome. Global Liver Institute, European Liver Patients' Association - ELPA, LPI LIVER PATIENTS INTERNATIONAL, Fatty Liver Foundation, NASH kNOWledge, Community Liver Alliance, American Liver Foundation, Midsouth Sober Living, American Association for the Study of Liver Diseases (AASLD), EASL | The Home of Hepatology
Fatty Liver Alliance
Non-profit Organizations
Awareness, Education, Research and Advocacy to support patients living with fatty liver disease and MASH.
About us
Our mission is to raise awareness about the risks, causes and complications of fatty liver disease and help those already diagnosed with non-alcoholic fatty liver disease (NAFLD/MASLD) and non-alcoholic steatohepatitis (NASH/MASH) by advocating for access to approved treatments and care.
- Website
-
http://www.fattyliver.ca
External link for Fatty Liver Alliance
- Industry
- Non-profit Organizations
- Company size
- 2-10 employees
- Headquarters
- Toronto, Ontario
- Type
- Nonprofit
- Founded
- 2021
Locations
-
Primary
Toronto, Ontario, CA
Updates
-
Even with effective vaccines, "there are still 254 million people with HBV surface antigen (HBsAg) positive chronic hepatitis B (CHB), of which 16–67% may have concurrent MASLD." (Journal of Viral Hepatitis) What is the impact of MASLD on patients who have Hepatitis B? Dr. Carla Coffin from University of Calgary and colleagues studied this relationship and outcomes and here Pharmacy Practice News summarizes the findings. Reference to original paper: 'Assessment of HBV variants and novel viral and immune biomarkers in chronic hepatitis B patients with metabolic dysfunction associated steatotic liver disease': https://lnkd.in/gs-t-KFG "Subjects with MetS and steatosis showed lower HBV markers (p < .01), higher HBV S diversity (p = .02) and greater frequency of HBV variants associated with host-anti-viral immune escape." American Association for the Study of Liver Diseases (AASLD), EASL | The Home of Hepatology, Global NASH Council, European Liver Patients' Association - ELPA, Global Liver Institute
-
The future is bright for MASLD and MASH and patients and diagnostic non-invasive assessments continue to improve. Here’s a great summary of a new paper just out, and a commentary from Zobair Younossi about the findings. Link to summary: https://lnkd.in/gufpVwnY Original paper: ‘Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease’. JAMA. 2024 Apr 16;331(15):1287-1297. Https://https://lnkd.in/g3TQub6C American Association for the Study of Liver Diseases (AASLD), EASL | The Home of Hepatology, Canadian Association for the Study of the Liver, Global Liver Institute, Louise Campbell MSc (AP), RMN, RN, FRCP, Michael P. McTighe, LiverScan European Liver Patients' Association - ELPA, Mazen Noureddin, MD, MHSc, Naim Alkhouri, MD, FAASLD, Echosens, Aegle Medical, KNS Canada Inc.
-
-
A heartwarming post to start your week AND it is relevant to MASLD and MASH. Madeleine Chang is a high school senior at Arnold O. Beckman High School in Orange County, California,. She has a strong interest in biology and medicine, and has (with her brother Devon Chang, also a high-school student) been working with Dr. Mazen Noureddin, MD, MHSc, Hepatologist from Houston Research Institute on MASLD research for the last two to three years. We used the words 'heart warming' because it is so great seeing people as young as high-school students passionately exploring science in an effort to help patients! Madeleine is the first author of this paper! Together with other notable co-authors including Dr. Naim Alkhouri, MD, FAASLDi, the late and very missed Dr. Stephen Harrison, Devon Chang, Sudha Kodali and Mark Ghobrial wrote a paper that was very recently published in Clinical Gastroenterology and Hepatology, titled, "Degree of Discordance between FIB-4 and Transient Elastography: An application of current guidelines on general population cohort". Key takeaways of this video chat discussion include: 1. 10% Misclassification Risk: FIB-4, while a cost-effective and widely used non-invasive test, misclassified 10% of patients as low-risk, who were later found to be at higher risk based on transient elastography. 2. Importance of Follow-Up Testing: The study recommends that primary care physicians consider annual or biannual testing and explore additional tools like transient elastography or machine learning models to improve accuracy. 3. Focus on High-Risk Patients: Patients with comorbidities such as type 2 diabetes and higher BMI are more prone to misclassification, underscoring the need for careful monitoring in these populations. 4. Need for Continued Research: The findings suggest that ongoing research and refinement of non-invasive tests are crucial to improve patient outcomes and reduce the burden on specialist services. Madeleine shared this: "Although we did highlight some of the limitations in our study, currently FIB-4 is highly effective and widely utilized and a cost-effective test that is accessible to primary care physicians. So we do recommend to continue on with the pathway. As Dr. Noureddin mentioned, we're just suggesting the idea of exploring possible alternatives, such as we highlighted in the paper, SAFE Score, MASEF, NIS-2, and machine learning models." https://lnkd.in/g4pxZrVX American Association for the Study of Liver Diseases (AASLD), EASL | The Home of Hepatology, Global Liver Institute, Canadian Association for the Study of the Liver, Houston Liver Institute, Arizona Liver Health, Summit Clinical Research, European Liver Patients' Association - ELPA, LPI LIVER PATIENTS INTERNATIONAL, Echosens, Aegle Medical, KNS Canada Inc., Liver Scan Direct
How Aligned are FIB-4 and Fibroscan Assessments?
fattyliver.ca
-
Findings in this study are that patients with MASLD and Type-2 Diabetes progress faster (liver stiffness measurement) than those with MASLD alone. “The investigators concluded, “[W]e demonstrate that LSM progresses faster in T2DM compared to people without T2DM. T2DM remained a strong and independent predictor for LSM progression, even after adjustment for multiple confounders. Mean HbA1C was independently associated with LSM progression and regression, suggesting that glycemic control may be an important determinant of disease progression in MASLD.” https://lnkd.in/g2WtnZKX
Liver Stiffness Index Progression in MASLD Predicted With Type 2 Diabetes
https://www.renalandurologynews.com
-
What a great discussion we will have highlighting the key take-aways from Paris MASH and more importantly how they can be applied in the real world clinical and research settings.
Don’t miss out on the latest insights in MASH clinical trials! Join Michael Betel, Attila Timar-Pereguin, Jörn M. Schattenberg, Naim Alkhouri, MD, FAASLD, and Mark Swain for a BrightTALK webinar as they unpack key takeaways from the Paris MASH Meeting. Register today to get ahead in MASH research: https://ow.ly/GIL450T4pCv
Paris MASH Meeting Takeaways: Real-World Applications & Innovations in MASH Research & Care
brighttalk.com
-
Today, we're taking a crucial step forward in advocating for Canadians diagnosed with MASH (Metabolic dysfunction-Associated Steatohepatitis). We've launched a petition asking Madrigal Pharmaceuticals to apply to Health Canada, so that Canadians can have access to Rezdiffra—a vital treatment for MASH. Your support is essential! Please take a moment to sign our petition and share this with your network. Together, we can make a difference! 🔗 Sign the Petition Here: https://lnkd.in/g-d8tvYS 🔗 Read Our Media Release: https://lnkd.in/gEmmSX37 Thank you for standing with us in this important cause. #MASH #Rezdiffra #HealthcareAdvocacy #LiverHealth #Canada American Association for the Study of Liver Diseases (AASLD), European Liver Patients' Association - ELPA, Global NASH Council, Canadian Association for the Study of the Liver, Canadian Association of Hepatology Nurses, Canadian Association of Gastroenterology, Canadian Family Physician, Barcelona Institute for Global Health (ISGlobal), Global Liver Institute, European Liver Patients' Association - ELPA, LPI LIVER PATIENTS INTERNATIONAL, Lanre Tunji-Ajayi, M.S.M. Obesity Canada – Obésité Canada, Obesity Matters, The Forum for Collaborative Research: Liver Forum
Urgent Call to Action: Canadians Deserve Equal Access to Life-Saving Liver Treatment--Sign the Petition Now!
newswire.ca
-
Chronic Kidney Disease (CKD) can be predicted more frequently in Steatotic Liver Disease (SLD) that involves metabolic co-morbidities as found in this paper just out, covering a 10 year period. The new(ish) nomenclature helped differentiate the metabolic versus non-metabolic possible versions of SLD. "Using the new nomenclature of steatotic liver disease (SLD) including metabolic dysfunction-associated SLD (MASLD), MASLD and increased alcohol intake (MetALD), and alcohol-associated liver disease (ALD), the relationship between each category of SLD and chronic kidney disease (CKD) was investigated. Both MASLD and ALD, but not SLD without metabolic dysfunction, were independently associated with the development of CKD during a 10-year follow-up period." Hepatology Research JSH: 07 August 2024 DOI: https://lnkd.in/gCKdjg6h American Association for the Study of Liver Diseases (AASLD), EASL | The Home of Hepatology, Canadian Association for the Study of the Liver, Global Liver Institute, Maru/Mary Rinella, European Liver Patients' Association - ELPA
Metabolic dysfunction‐associated steatotic liver disease (SLD) and alcohol‐associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic kidney disease during a 10‐year follow‐up period
onlinelibrary.wiley.com
-
"Shift work was significantly associated with the development of NAFLD among young workers in their 20s. This association was significantly more pronounced among young female workers and young workers with poor sleep quality across all sexes." "Shift workers have shorter sleep durations and poorer sleep quality. Previous studies on sleep restriction in young men and women have reported that plasma leptin levels decrease, and ghrelin levels increase. This increases both appetite and fat intake, subsequently causing obesity and diabetes, leading to an increased risk of developing NAFLD." Paper DOI: https://lnkd.in/gDGw2X9u Scientific Reports volume 14, Article number: 19367 (2024) American Association for the Study of Liver Diseases (AASLD), EASL | The Home of Hepatology, Global NASH Council, Canadian Association for the Study of the Liver, European Liver Patients' Association - ELPA, Global Liver Institute, LPI LIVER PATIENTS INTERNATIONAL, NASH kNOWledge, Gina Madison, Summit Clinical Research, Arizona Liver Health, Houston Liver Institute https://lnkd.in/gf3gjHcC
Shift work and non-alcoholic fatty liver disease in young, healthy workers - Scientific Reports
nature.com
-
As we seek more accurate measures beyond BMI to assess obesity-related cardiometabolic risks, such as those critical in diagnosing and managing MASLD and MASH, the importance of understanding individual fat distribution and visceral adiposity becomes increasingly clear. BMI has long been used as the primary measure for diagnosing obesity and determining treatment, but it is an incomplete measure that fails to account for factors such as muscle mass, fat distribution, gender, and ethnicity. Particularly, it does not adequately reflect the cardiometabolic risks associated with visceral fat, which varies significantly across different populations. Although new technologies and methods may improve risk assessment, traditional clinical evaluations, combined with an understanding of individual patient histories and physical examinations, remain crucial. American Association for the Study of Liver Diseases (AASLD), EASL | The Home of Hepatology, Global NASH Council, Canadian Association for the Study of the Liver, The Forum for Collaborative Research: Liver Forum, European Liver Patients' Association - ELPA, Obesity Matters, LPI LIVER PATIENTS INTERNATIONAL, Medscape
Is Adipose Tissue a Better Measure for Obesity Than BMI?
medscape.com